Calvin Lam
麻豆入口
Filters
Guotai Junan merger with Haitong and concurrent placement of shares
We advised Guotai Junan Securities on the transaction, creating the largest securities company in China
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Zhejiang Expressway $860 million rights issue
The H shares are listed on the Hong Kong Stock Exchange聽
MedSci Healthcare Holdings HK$608 million IPO
We advised MedSci on its IPO and HKEX listing
ZJLD Group HK$5.3 billion IPO聽
We advised ZJLD on its IPO and HKEX listing
Bilibili convertible notes exchange and concurrent follow-on equity offering
The transaction involved a convertible notes exchange and a concurrent follow-on offering of ADSs
Tuya global offering and dual primary listing on the Hong Kong Stock Exchange
We advised Tuya Inc. on its HK$141 million global offering and dual primary listing on the HKEX